SomaLogic (NASDAQ:SLGC) & Bioqual (OTCMKTS:BIOQ) Head-To-Head Survey

SomaLogic (NASDAQ:SLGCGet Rating) and Bioqual (OTCMKTS:BIOQGet Rating) are both small-cap business services companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

Insider and Institutional Ownership

44.6% of SomaLogic shares are owned by institutional investors. 39.2% of Bioqual shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares SomaLogic and Bioqual’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SomaLogic $81.63 million 14.97 -$87.55 million N/A N/A
Bioqual $57.68 million 1.40 $6.33 million $6.28 14.33

Bioqual has lower revenue, but higher earnings than SomaLogic.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for SomaLogic and Bioqual, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SomaLogic 0 0 3 0 3.00
Bioqual 0 0 0 0 N/A

SomaLogic presently has a consensus price target of $15.33, suggesting a potential upside of 128.51%. Given SomaLogic’s higher possible upside, analysts plainly believe SomaLogic is more favorable than Bioqual.


This table compares SomaLogic and Bioqual’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SomaLogic N/A -30.93% -19.50%
Bioqual 9.38% N/A N/A

SomaLogic Company Profile (Get Rating)

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

Bioqual Company Profile (Get Rating)

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is headquartered in Rockville, Maryland.

Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with's FREE daily email newsletter.